logo-loader
Arix Bioscience PLC

Arix Bioscience invests US$15mln in sickle cell treatment developer Imara

The health and life science investor said the sum would give it a 10% stake in the company and expand the breadth of its portfolio

Sickle blood cells
Sickle cell disease is a group of inherited that cause red blood cells to be sickle-shaped meaning they do not survive as long as healthy cells

Arix Bioscience PLC (LON:ARIX) said it has invested US$15mln (£11.3mln) in Imara, a company developing treatments for sickle cell disease.

The health and life science investor said the sum would give it a 10% stake in the company and expand the breadth of its portfolio.

READ: Arix Bioscience appoints Joe Anderson CEO in boardroom reshuffle

Based in Massachusetts, Imara is developing a treatment designed to inhibit the underlying causes of sickle cell disease, a group of inherited conditions that cause red blood cells to be sickle-shaped meaning they do not survive as long as healthy cells and can become stuck in blood vessels.

This can lead to symptoms such as anaemia when blood cells can’t carry enough oxygen around the body, as well as an increased risk of serious infections and painful episodes called sickle cell crises which can last up to a week.

The treatment, known as IMR-687, has already successfully completed a phase 1 study in healthy volunteers and is currently in a global phase 2a study using adult sickle cell patients.

Joe Anderson, chief executive of Arix, said it would be working with Imara and its co-investors to help “accelerate the development” of the company.

“Sickle cell disease affects a large and growing population across the world and is devastating for both patients and families. Imara is led by an exceptional team developing a novel, compelling approach to treating this difficult disease.”

In early trading Monday, Arix shares were down 1.7% at 145p.

Quick facts: Arix Bioscience PLC

Price: £1.23

Market: LSE
Market Cap: £166.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience 'building a very exciting, diversified healthcare company'

Dr Joe Anderson, chief executive of Arix Bioscience Plc (LON:ARIX) runs Proactive Investors through the company's strategy and outlook. ''We're focused on the innovation end of healthcare, which is exactly where we believe the value is in healthcare today'', Anderson says.

on 19/5/17

2 min read